Quarterly Cashflow Report
Melbourne, Australia; Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 June 2018.
Starpharma CEO Dr Jackie Fairley interviewed by Alan Kohler for The Constant Investor
VivaGel® BV NDA advances to next stage of FDA review
Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that the US FDA has completed its filing review of the VivaGel® BV New Drug Application (NDA), with no issues identified, and confirmed its progress to the next stage.
Starpharma CEO Dr Jackie Fairley interviewed by Alan Kohler on Talking Business
|
Starpharma CEO Dr Jackie Fairley speaks with Alan Kohler about how the company has taken VivaGel® BV from discovery to market and developed commercial products with its proprietary dendrimer technology platform. |
To listen to the podcast, click here.
Starpharma CEO Jackie Fairley featured on Qantas’ inflight magazine Travel Insider
Starpharma CEO Dr Jackie Fairley was featured in Qantas’ inflight magazine. To read the article, click here.
Starpharma licenses VivaGel® BV to Mundipharma for Europe
Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) and Mundipharma today announced they have signed a licence agreement for the sales and marketing rights to VivaGel®BV for 43 countries in Europe, Russia, the Commonwealth of Independent States (CIS) and the balance of countries in Latin America. This deal builds on the VivaGel® BV licence signed with Mundipharma in May 2018 for Asia, the Middle East, Africa and parts of Latin America.
Mundipharma licenses Starpharma’s VivaGel® BV
Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) and Mundipharma today announced they have signed a multi-region licence for the sales and marketing rights to VivaGel® BV in Asia (including China, Japan and Korea), the Middle East, Africa and the majority of Latin America.
Quarterly Cashflow Report
Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2018.
Starpharma completes US New Drug Application for VivaGel® BV
Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that its rolling new drug application (NDA) for VivaGel® BV including two indications, for the treatment of bacterial vaginosis (BV) and prevention of BV, has been completed, and the final module of the NDA will be submitted to the US Food and Drug Administration (FDA) on Monday 30 April 2018 (US time).
VivaGel® BV - Product Information and Independent Market Research
VivaGel® BV - Product Information and Independent Market Research